Silexion underwent a major financial restructuring following its August 2024 business combination, dramatically improving its balance sheet with a 405% cash increase and positive stockholders' equity turnaround.
The company has successfully transitioned from financial distress to a stronger capital position, moving from negative $4.0M to positive $2.6M in stockholders' equity while significantly reducing total liabilities by 33%. However, the 29% increase in operating cash burn to $10.8M, combined with increased R&D spending, suggests accelerated drug development activities that will require careful cash management despite the improved liquidity position.
Silexion's financials reflect a dramatic post-merger transformation, with cash and equivalents surging 405% to $6.0M and total assets increasing 152% to $7.2M, while total liabilities declined 33% to $4.6M. The company moved from a $4.0M stockholders' deficit to a positive $2.6M equity position, though net losses remain substantial at $11.9M despite a 28% improvement. Operating cash burn worsened by 29% to $10.8M alongside 23% higher R&D expenses, indicating intensified development activities that will test the company's improved but still limited cash resources.
Net interest income grew 453.6% — benefiting from rate environment or loan book expansion.
Cash position surged 404.7% — strong cash generation or capital raise providing significant financial cushion.
Current assets grew 195% — improving short-term liquidity or inventory/receivables build.
Equity base grew 165.3% — retained earnings accumulation or equity issuance strengthening the balance sheet.
Asset base grew 152% — expansion through organic growth, acquisitions, or capital deployment.
Capex reduced 59.1% — investment cycle winding down or capital discipline; may improve near-term free cash flow.
Liabilities reduced 32.7% — deleveraging improves balance sheet strength and financial flexibility.
Operating cash flow softened — monitor whether temporary working capital timing or structural deterioration.
Net income grew 27.9% — bottom-line growth signals improving overall business health.
R&D investment increased 22.8% — signals commitment to future product development, though near-term margin impact.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →